Log in to search using one of your social media accounts:

 

Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis

ConclusionAdding cisplatin to long-term S-1 monotherapy did not significantly improve the outcome of CY+ advanced gastric cancer patients.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 12 August 2017 Source:Genomics, Proteomics & Bioinformatics Author(s): Lin Yang, Shanshan Zou, Chang Shu, Yan Song, Yong-Kun Sun, Wen Zhang, Aiping Zhou, Xinghua Yuan, Yi Yang, Songnian Hu Gastric carcinomaisaheterogeneous malignant disease involving genetic factors. To identify predictive markers for gastric cancer treatment in Chinese patients, we evaluated the association between polymorphisms of the gene encoding cytochrome P450 2A6 (CYP2A6) and outcomes of S-1 plus oxaliplatin (SOX) chemotherapy treatment. Clinical data on 60 consecutive gastric cancer patients receiving SOX reg...
Source: Genomics, Proteomics and Bioinformatics - Category: Bioinformatics Source Type: research
Abstract Gastric carcinomaisaheterogeneous malignant disease involving genetic factors. To identify predictive markers for gastric cancer treatment in Chinese patients, we evaluated the association between polymorphisms of the gene encoding cytochrome P450 2A6 (CYP2A6) and outcomes of S-1 plus oxaliplatin (SOX) chemotherapy treatment. Clinical data on 60 consecutive gastric cancer patients receiving SOX regimen were collected prospectively. We sequenced all exons of CYP2A6 and a total of 22 different polymorphisms were detected in the present study. Comprehensive analyses of these genetic polymorphisms were perfor...
Source: Genomics Proteomics ... - Category: Genetics & Stem Cells Authors: Tags: Genomics Proteomics Bioinformatics Source Type: research
CONCLUSIONS: This registry revealed that half patients with oesophageal cancer were operated in hospitals with less than 10 cases per year at the Comunidad Valenciana. Also, it detected capacity improvement for some clinical outcomes of oesophageal and gastric carcinomas. PMID: 28807364 [PubMed - as supplied by publisher]
Source: Cirugia eEspanola - Category: Surgery Authors: Tags: Cir Esp Source Type: research
CONCLUSIONS: Laparoscopic HIPEC was well tolerated, and an encouraging number of patients demonstrated an absence of peritoneal disease after HIPEC and were able to undergo gastrectomy. Comparative studies will be required to clarify survival benefits. PMID: 28799004 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
Conclusion For patients with rare tumors, CRS and HIPEC is feasible with an acceptable perioperative morbidity and mortality. To improve knowledge in patient selection and outcome, rare tumors treated with CRS and HIPEC should be documented in central databases (as for example BIG RENAPE, Pierre-Benite, France).
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
Abstract Gastric carcinoma (GC) is the 2nd most common cause of cancer-related death. Despite advances in conventional treatment and surgical interventions, a high percentage of GC patients still have poor survival. Recently, immunotherapy has become a promising approach to treat GC. Here, we present preclinical and clinical studies encouraging the use of vaccination, adoptive T-cell therapy (ACT), and immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The ongoing immunotherapy clinical trials have ...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
We report an 80 year old male patient diagnosed with an advanced adenocarcinoma of the oesophagogastric junction (uT3 uN + cM0; Siewert II). The initial external HER2 test was negative (HER2 value 1 +) but was repeated in-house. On the basis of more extensive biopsies focal but strong HER2 positivity (HER2 value 3 +, ~10 % of the tumor cells positive) was demonstrated. The patient subsequently received a combination of oxaliplatin, 5-fluorouracil/folinic acid and trastuzumab, resulting in an improvement of symptoms and a tumor regression. The discrepancy of the two HER2 tests performed was caused by heterogeneity of ...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
ABSTRACT We have established an orthotopic nude‐mouse model of gastric cancer carcinomatosis peritonitis, a recalcitrant disease in human patients. Human MKN45 poorly‐differentiated human gastric cancer cells developed carcinomatosis peritonitis upon orthotopic transplantation in nude mice. The MKN45 cells expressed the fluorescent ubiquitination‐based cell cycle indicator (FUCCI) that color codes the phases of the cell cycle. The intra‐peritoneal tumors and ascites contained mostly quiescent G1/Go cancer cells visualized as red by FUCCI imaging. Cisplatinum (CDDP) treatment did not reduce bloody ascites, and large...
Source: Journal of Cellular Biochemistry - Category: Biochemistry Authors: Tags: Article Source Type: research
Conditions:   Gastric Cancer;   Peritoneal Carcinomatosis Interventions:   Procedure: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure;   Procedure: Cytoreductive surgery alone Sponsor:   Hospices Civils de Lyon Completed - verified July 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Biochemistry - Category: Biochemistry Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Cytology | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Study